Building translational bridges in idiopathic pulmonary fibrosis research: from epithelial dysfunction to dysregulated macrophage polarisation and fibrogenesis

Abstract excerpt

Extract Idiopathic pulmonary fibrosis (IPF) remains among the most devastating interstitial lung diseases (ILDs), marked by progression, impaired quality of life, poor prognosis and limited therapeutic options. Despite two approved antifibrotic compounds, nintedanib and pirfenidone, and probably a third to come (nerandomilast), IPF patients continue to face unfavourable outcomes, with no available therapy capable...